US 12,133,901 B2
PSMA ligand targeted compounds and uses thereof
James Basilion, Cleveland, OH (US); Clemens Burda, Cleveland, OH (US); Dong Luo, Cleveland, OH (US); and Xinning Wang, Cleveland, OH (US)
Assigned to CASE WESTERN RESERVE UNIVERSITY, Cleveland, OH (US)
Appl. No. 17/424,084
Filed by CASE WESTERN RESERVE UNIVERSITY, Cleveland, OH (US)
PCT Filed Jan. 21, 2020, PCT No. PCT/US2020/014460
§ 371(c)(1), (2) Date Jul. 19, 2021,
PCT Pub. No. WO2020/150740, PCT Pub. Date Jul. 23, 2020.
Claims priority of provisional application 62/794,251, filed on Jan. 18, 2019.
Prior Publication US 2022/0096663 A1, Mar. 31, 2022
Int. Cl. A61K 49/04 (2006.01); A61K 9/14 (2006.01); A61K 33/242 (2019.01); A61K 41/00 (2020.01); A61K 47/54 (2017.01); A61P 35/00 (2006.01)
CPC A61K 49/0423 (2013.01) [A61K 9/14 (2013.01); A61K 33/242 (2019.01); A61K 41/0038 (2013.01); A61K 47/542 (2017.08); A61P 35/00 (2018.01)] 24 Claims
 
1. A composition for detecting and/or treating cancer, the composition comprising a plurality of compounds that include formula (I):

OG Complex Work Unit Chemistry
wherein:
n and n1 are each independently 1, 2, 3, or 4;
L is an optionally substituted aliphatic or heteroaliphatic linking group;
B comprises at least one negatively charged amino acid; and
Z has the formula

OG Complex Work Unit Chemistry
 wherein Z is directly or indirectly linked to B.